Why did European Radiology reject my radiomic biomarker paper? How to correctly evaluate imaging biomarkers in a clinical setting - Sorbonne Université
Article Dans Une Revue European Radiology Année : 2021

Why did European Radiology reject my radiomic biomarker paper? How to correctly evaluate imaging biomarkers in a clinical setting

Résumé

This review explains in simple terms, accessible to the non-statistician, general principles regarding the correct research methods to develop and then evaluate imaging biomarkers in a clinical setting, including radiomic biomarkers. The distinction between diagnostic and prognostic biomarkers is made and emphasis placed on the need to assess clinical utility within the context of a multivariable model. Such models should not be restricted to imaging biomarkers and must include relevant disease and patient characteristics likely to be clinically useful. Biomarker utility is based on whether its addition to the basic clinical model improves diagnosis or prediction. Approaches to both model development and evaluation are explained and the need for adequate amounts of representative data stressed so as to avoid underpowering and overfitting. Advice is provided regarding how to report the research correctly.

Domaines

Imagerie
Fichier principal
Vignette du fichier
Halligan2021_Article_WhyDidEuropeanRadiologyRejectM.pdf (267.59 Ko) Télécharger le fichier
Origine Publication financée par une institution

Dates et versions

hal-03230630 , version 1 (20-05-2021)

Identifiants

Citer

Steve Halligan, Yves Menu, Sue Mallett. Why did European Radiology reject my radiomic biomarker paper? How to correctly evaluate imaging biomarkers in a clinical setting. European Radiology, In press, ⟨10.1007/s00330-021-07971-1⟩. ⟨hal-03230630⟩
20 Consultations
22 Téléchargements

Altmetric

Partager

More